Meta-analysis of copper and iron in Parkinson's disease brain and biofluids.

Genoud, S; Senior, AM; Hare, DJ; Double, KL

Meta-analysis of copper and iron in Parkinson's disease brain and biofluids.

Genoud, S

Senior, AM Hare, DJ Double, KL

Permalink

Publisher:: WILEY
Publication Type:: Journal Article
Citation:: Movement disorders : official journal of the Movement Disorder Society, 2020, 35, (4), pp. 662-671
Issue Date:: 2020

Closed Access

	Filename	Description	Size
	mds.27947.pdf		1.48 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Genoud, S https://orcid.org/0000-0001-8787-4541
dc.contributor.author	Senior, AM
dc.contributor.author	Hare, DJ
dc.contributor.author	Double, KL
dc.date.accessioned	2020-12-18T02:51:47Z
dc.date.available	2019-11-20
dc.date.available	2020-12-18T02:51:47Z
dc.date.issued	2020
dc.identifier.citation	Movement disorders : official journal of the Movement Disorder Society, 2020, 35, (4), pp. 662-671
dc.identifier.issn	0885-3185
dc.identifier.issn	1531-8257
dc.identifier.uri	http://hdl.handle.net/10453/144838
dc.description.abstract	BACKGROUND:Variations in study quality and design complicate interpretation of the clinical significance of consistently reported changes in copper and iron levels in human Parkinson's disease brain and biofluids. METHODS:We systematically searched literature databases for quantitative reports of biometal levels in the degenerating substantia nigra (SN), CSF, serum, and plasma in Parkinson's disease compared with healthy age-matched controls and assessed the quality of these publications. The primary outcomes of our analysis confirmed SN copper and iron levels are decreased and increased, respectively, in the Parkinson's disease brain. We applied a novel Quality Assessment Scale for Human Tissue to categorize the quality of individual studies and investigated the effects of study quality on our outcomes. We undertook a random-effects meta-analysis and meta-regression subgroup analysis. RESULTS:In the 18 eligible studies identified (211 Parkinson's disease, 215 control cases), SN copper levels were significantly lower (d, -2.00; 95% CI, -2.81 to -1.19; P < 0.001), and iron levels were significantly higher (d, 1.31; 95% CI, 0.38-2.24; P < 0.01) in Parkinson's disease. No changes were detected in CSF, serum, or plasma for any metals (29 studies; 2443 Parkinson's disease and 2183 control cases) except serum iron, which was lower in Parkinson's disease (14 studies; 1177 Parkinson's disease and 1447 control cases). CONCLUSIONS:Reductions in copper levels and elevations in iron were confirmed as characteristic of the degenerating SN of Parkinson's disease. Iron in serum was also changed, but in the opposite direction to that in the SN and to a lesser extent. © 2019 International Parkinson and Movement Disorder Society.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	WILEY
dc.relation.ispartof	Movement disorders : official journal of the Movement Disorder Society
dc.relation.isbasedon	10.1002/mds.27947
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences, 1106 Human Movement and Sports Sciences, 1109 Neurosciences
dc.subject.classification	Neurology & Neurosurgery
dc.title	Meta-analysis of copper and iron in Parkinson's disease brain and biofluids.
dc.type	Journal Article
utslib.citation.volume	35
utslib.location.activity	United States
utslib.for	1103 Clinical Sciences
utslib.for	1106 Human Movement and Sports Sciences
utslib.for	1109 Neurosciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2020-12-18T02:51:34Z
pubs.issue	4
pubs.publication-status	Published
pubs.volume	35
utslib.citation.issue	4

Abstract:

BACKGROUND:Variations in study quality and design complicate interpretation of the clinical significance of consistently reported changes in copper and iron levels in human Parkinson's disease brain and biofluids. METHODS:We systematically searched literature databases for quantitative reports of biometal levels in the degenerating substantia nigra (SN), CSF, serum, and plasma in Parkinson's disease compared with healthy age-matched controls and assessed the quality of these publications. The primary outcomes of our analysis confirmed SN copper and iron levels are decreased and increased, respectively, in the Parkinson's disease brain. We applied a novel Quality Assessment Scale for Human Tissue to categorize the quality of individual studies and investigated the effects of study quality on our outcomes. We undertook a random-effects meta-analysis and meta-regression subgroup analysis. RESULTS:In the 18 eligible studies identified (211 Parkinson's disease, 215 control cases), SN copper levels were significantly lower (d, -2.00; 95% CI, -2.81 to -1.19; P < 0.001), and iron levels were significantly higher (d, 1.31; 95% CI, 0.38-2.24; P < 0.01) in Parkinson's disease. No changes were detected in CSF, serum, or plasma for any metals (29 studies; 2443 Parkinson's disease and 2183 control cases) except serum iron, which was lower in Parkinson's disease (14 studies; 1177 Parkinson's disease and 1447 control cases). CONCLUSIONS:Reductions in copper levels and elevations in iron were confirmed as characteristic of the degenerating SN of Parkinson's disease. Iron in serum was also changed, but in the opposite direction to that in the SN and to a lesser extent. © 2019 International Parkinson and Movement Disorder Society.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/144838